203 related articles for article (PubMed ID: 37990341)
21. Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase δ mutation in human cells.
Mertz TM; Baranovskiy AG; Wang J; Tahirov TH; Shcherbakova PV
Oncogene; 2017 Aug; 36(31):4427-4433. PubMed ID: 28368425
[TBL] [Abstract][Full Text] [Related]
22. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
[TBL] [Abstract][Full Text] [Related]
23. Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction.
Hamzaoui N; Alarcon F; Leulliot N; Guimbaud R; Buecher B; Colas C; Corsini C; Nuel G; Terris B; Laurent-Puig P; Chaussade S; Dhooge M; Madru C; Clauser E
Genet Med; 2020 Sep; 22(9):1533-1541. PubMed ID: 32424176
[TBL] [Abstract][Full Text] [Related]
24. Polymerase proofreading-associated polyposis: a new, dominantly inherited syndrome of hereditary colorectal cancer predisposition.
Church JM
Dis Colon Rectum; 2014 Mar; 57(3):396-7. PubMed ID: 24509466
[TBL] [Abstract][Full Text] [Related]
25. The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management.
Palles C; Martin L; Domingo E; Chegwidden L; McGuire J; Cuthill V; Heitzer E; ; Kerr R; Kerr D; Kearsey S; Clark SK; Tomlinson I; Latchford A
Fam Cancer; 2022 Apr; 21(2):197-209. PubMed ID: 33948826
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
Yao J; Gong Y; Zhao W; Han Z; Guo S; Liu H; Peng X; Xiao W; Li Y; Dang S; Liu G; Li L; Huang T; Chen S; Song L
Sci Rep; 2019 Oct; 9(1):15767. PubMed ID: 31673068
[TBL] [Abstract][Full Text] [Related]
27. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
Ma X; Riaz N; Samstein RM; Lee M; Makarov V; Valero C; Chowell D; Kuo F; Hoen D; Fitzgerald CWR; Jiang H; Alektiar J; Alban TJ; Juric I; Parthasarathy PB; Zhao Y; Sabio EY; Verma R; Srivastava RM; Vuong L; Yang W; Zhang X; Wang J; Chu LK; Wang SL; Kelly DW; Pei X; Chen J; Yaeger R; Zamarin D; Zehir A; Gönen M; Morris LGT; Chan TA
Nat Genet; 2022 Jul; 54(7):996-1012. PubMed ID: 35817971
[TBL] [Abstract][Full Text] [Related]
28. Constitutional POLE variants causing a phenotype reminiscent of constitutional mismatch repair deficiency.
Sehested A; Meade J; Scheie D; Østrup O; Bertelsen B; Misiakou MA; Sarosiek T; Kessler E; Melchior LC; Munch-Petersen HF; Pai RK; Schmuth M; Gottschling H; Zschocke J; Gallon R; Wimmer K
Hum Mutat; 2022 Jan; 43(1):85-96. PubMed ID: 34816535
[TBL] [Abstract][Full Text] [Related]
29. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours.
Andrianova MA; Chetan GK; Sibin MK; Mckee T; Merkler D; Narasinga RK; Ribaux P; Blouin JL; Makrythanasis P; Seplyarskiy VB; Antonarakis SE; Nikolaev SI
J Pathol; 2017 Nov; 243(3):331-341. PubMed ID: 28805995
[TBL] [Abstract][Full Text] [Related]
30. POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.
Magrin L; Fanale D; Brando C; Fiorino A; Corsini LR; Sciacchitano R; Filorizzo C; Dimino A; Russo A; Bazan V
Oncogene; 2021 Oct; 40(40):5893-5901. PubMed ID: 34363023
[TBL] [Abstract][Full Text] [Related]
31. POLE and POLD1 pathogenic variants in the proofreading domain in papillary thyroid cancer.
Siraj AK; Bu R; Arshad M; Iqbal K; Parvathareddy SK; Masoodi T; Ghazwani LO; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Endocr Connect; 2020 Oct; 9(9):923-932. PubMed ID: 32992294
[TBL] [Abstract][Full Text] [Related]
32. The burden of faulty proofreading in colon cancer.
Seshagiri S
Nat Genet; 2013 Feb; 45(2):121-2. PubMed ID: 23358219
[TBL] [Abstract][Full Text] [Related]
33. A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency.
Wimmer K; Beilken A; Nustede R; Ripperger T; Lamottke B; Ure B; Steinmann D; Reineke-Plaass T; Lehmann U; Zschocke J; Valle L; Fauth C; Kratz CP
Fam Cancer; 2017 Jan; 16(1):67-71. PubMed ID: 27573199
[TBL] [Abstract][Full Text] [Related]
34. The first case report of polymerase proofreading-associated polyposis in POLD1 variant, c.1433G>A p.S478N, in Japan.
Ito T; Nomizu T; Eguchi H; Kamae N; Dechamethakun S; Akama Y; Endo G; Sugano K; Yoshida T; Okazaki Y; Ishida H
Jpn J Clin Oncol; 2020 Sep; 50(9):1080-1083. PubMed ID: 32548621
[TBL] [Abstract][Full Text] [Related]
35. Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma.
Vande Perre P; Siegfried A; Corsini C; Bonnet D; Toulas C; Hamzaoui N; Selves J; Chipoulet E; Hoffmann JS; Uro-Coste E; Guimbaud R
Fam Cancer; 2019 Apr; 18(2):173-178. PubMed ID: 30368636
[TBL] [Abstract][Full Text] [Related]
36. Novel mutations and phenotypic associations identified through APC, MUTYH, NTHL1, POLD1, POLE gene analysis in Indian Familial Adenomatous Polyposis cohort.
Khan N; Lipsa A; Arunachal G; Ramadwar M; Sarin R
Sci Rep; 2017 May; 7(1):2214. PubMed ID: 28533537
[TBL] [Abstract][Full Text] [Related]
37. DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
Ostroverkhova D; Tyryshkin K; Beach AK; Moore EA; Masoudi-Sobhanzadeh Y; Barbari SR; Rogozin IB; Shaitan KV; Panchenko AR; Shcherbakova PV
Cell Rep; 2024 Jan; 43(1):113655. PubMed ID: 38219146
[TBL] [Abstract][Full Text] [Related]
38. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
[TBL] [Abstract][Full Text] [Related]
39. Distinctive genomic characteristics in
He J; Ouyang W; Zhao W; Shao L; Li B; Liu B; Wang D; Han-Zhang H; Zhang Z; Shao L; Li W
Ann Transl Med; 2021 Jan; 9(2):129. PubMed ID: 33569431
[TBL] [Abstract][Full Text] [Related]
40. Characterization of POLE c.1373A > T p.(Tyr458Phe), causing high cancer risk.
Rocque MJ; Leipart V; Kumar Singh A; Mur P; Olsen MF; Engebretsen LF; Martin-Ramos E; Aligué R; Sætrom P; Valle L; Drabløs F; Otterlei M; Sjursen W
Mol Genet Genomics; 2023 May; 298(3):555-566. PubMed ID: 36856825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
